

## PATENT ABSTRACTS OF JAPAN

(11)Publication number : 08-099869

(43)Date of publication of application : 16.04.1996

---

(51)Int.Cl. A61K 9/48  
A61K 47/04  
A61K 47/22

---

---

(21)Application number : 07-219756 (71)Applicant : SHIONOGI & CO LTD  
(22)Date of filing : 04.08.1995 (72)Inventor : SAKUMA SATOSHI  
SUZUKI YUSUKE  
FUJII TOSHIO  
OGURA TOSHIHIRO  
TAKAGISHI YASUSHI

---

(30)Priority

Priority number : 06204322 Priority date : 05.08.1994 Priority country : JP

---

(54) **SOFT GELATIN CAPSULE PREVENTED FROM DETERIORATING AND ITS PRODUCTION**

(57)Abstract:

PURPOSE: To obtain a hard gelatin capsule, containing a specific amount of a free radical scavenger, capable of preventing the solubility from deteriorating and insolubilizing with time, having stable medicine releasability and useful for a sustained release pharmaceutical preparation, etc.

CONSTITUTION: This hard gelatin capsule contains a free radical scavenger such as one or more selected from the group consisting of a pharmaceutically permissible salt of sulfurous acid, a pharmaceutically permissible salt of hydrogen sulfite and tocopherol, ascorbic acid, polyphosphoric acid, pyrophosphoric acid and a pharmaceutically permissible salt thereof in an amount of 0.01-5wt.% based on the total amount of the filling.

---

LEGAL STATUS

[Date of request for examination] 29.06.2001

[Date of sending the examiner's decision of rejection]

[Kind of final disposal of application other than the examiner's decision of rejection or application converted registration]

[Date of final disposal for application]

[Patent number]

[Date of registration]

[Number of appeal against examiner's decision of rejection]

[Date of requesting appeal against examiner's decision of rejection]

[Date of extinction of right]

Copyright (C); 1998,2003 Japan Patent Office

**\* NOTICES \***

**Japan Patent Office is not responsible for any damages caused by the use of this translation.**

- 1.This document has been translated by computer. So the translation may not reflect the original precisely.
- 2.\*\*\* shows the word which can not be translated.
- 3.In the drawings, any words are not translated.

---

**CLAIMS**

---

[Claim(s)]

[Claim 1] A hard gelatine capsule agent by which denaturation characterized by containing a free radical trapping agent 0.01 to 5% of the weight to the packing whole quantity was prevented.

[Claim 2] A hard gelatine capsule agent by which denaturation according to claim 1 it is [ denaturation ] 0.01 – 1 % of the weight was prevented for a content of a free radical trapping agent to the packing whole quantity.

[Claim 3] A hard gelatine capsule agent by which denaturation according to claim 1 or 2 whose free radical trapping agent is at least one sort chosen as a salt which can be permitted on medicine manufacture of a sulfurous acid, a salt which can be permitted on medicine manufacture of a hydrogen sulfite, and a list from a group which consists of a salt which can be permitted on a tocopherol, an ascorbic acid, polyphosphoric acid, pyrophosphoric acids, and these medicine manufacture was prevented.

[Claim 4] A hard gelatine capsule agent by which denaturation according to claim 3 whose free radical trapping agent is a sodium sulfite was prevented.

[Claim 5] A hard gelatine capsule agent by which denaturation according to claim 3 whose free radical trapping agent is a sodium hydrogensulfite was prevented.

[Claim 6] A hard gelatine capsule agent by which denaturation according to claim 3 whose free radical trapping agent is a sodium pyrophosphate or a potassium pyrophosphate was prevented.

[Claim 7] A manufacture method of a hard gelatine capsule agent that denaturation characterized by making a free radical trapping agent contain 0.01 to 5% of the weight to the packing whole quantity in a manufacture method of a hard gelatine capsule agent was prevented.

[Claim 8] A manufacture method of a hard gelatine capsule agent that denaturation according to claim 7 it is [ denaturation ] 0.01 – 1 % of the weight was prevented for a content of a free radical trapping agent to the packing whole quantity.

---

[Translation done.]

---

## \* NOTICES \*

**Japan Patent Office is not responsible for any damages caused by the use of this translation.**

- 1.This document has been translated by computer. So the translation may not reflect the original precisely.
- 2.\*\*\* shows the word which can not be translated.
- 3.In the drawings, any words are not translated.

---

**DETAILED DESCRIPTION**


---



---

**[Detailed Description of the Invention]**


---

**[0001]**

**[The technical field to which invention belongs]** A soluble fall with time and insolubilization are prevented and this invention relates to the hard gelatine capsule agent which has the stable drug release nature and by which denaturation was prevented, and its manufacture method.

**[0002]**

**[Description of the Prior Art]** Into the hard gelatine capsule, a hard gelatine capsule agent is what was filled up with packing, such as a drug, and is used for various kinds of purpose, such as improvement in the handling nature of a drug. In layout of the pharmaceutical preparation which contains an unstable drug in an acid, a sustained release drug, etc., since a difference is produced in a bioavailability among the persons prescribed a medicine for the patient when it considers as a tablet, generally considering as a hard gelatine capsule agent for the purpose of the evasion is performed.

**[0003]** For example, in order to make small the difference of the absorption coefficient in intestines by difference of the alimentary canal internal transmigration speed of a drug, basin system coating of the granulation of a drug is carried out with an enteric macromolecule or a water-insoluble nature macromolecule, and the method of filling up a hard gelatine capsule is often used. Moreover, in order to improve the wettability over the water of a poorly soluble drug, also when adding amphiphilic compounds, such as Tween (trade name), Span (trade name), and a polyethylene glycol (PEG), the method of making it into a hard gelatine capsule agent for evasion, such as deterioration of appearance, is used.

**[0004]** however, the case where a hard gelatine capsule is filled up with the amphiphilic compound which has granulation and the polyoxyethylene chain of the drug which carried out basin system coating in the above-mentioned method -- warming -- a hard gelatine capsule may deteriorate at the time of conservation, and drug release nature may fall remarkably As this cause, the polyoxyethylene chain in compounds and amphiphilic compounds, such as PEG used as a plasticizer in the case of basin system coating and citric-acid triethyl, etc. pyrolyzes, and gelatin can consider bridge formation and carrying out a polymerization between intramolecular or a molecule by peroxidation products, such as an aldehyde which this generates.

**[0005]** Using the organic solvent which does not use a plasticizer in the case of coating as the above-mentioned cure is mentioned. However, this method is not desirable from being in the orientation for there to be a problem of a residual solvent and for use of an organic solvent to be regulated from viewpoints, such as environmental pollution, in recent years. Although using plasticizers which do not generate a peroxide, such as a triacetin and glycerol monostearate, is also considered, there is a defect of dispersing odors, such as an acetic-acid smell to which the bad plasticizer itself carries out acidolysis, and acid resistance and drug release nature deteriorate with time, and the plasticity of a film is not desirable too.

**[0006]** Moreover, the method of adding protein, such as casein, soybean protein, skim milk, and a collagen, in an encapsulation object is learned as other methods (JP,51-15094,A). However, this method does not control generation of a peroxide, since it needs to make [ many ] an addition for acquiring a desired effect, a capsule enlarges it and it becomes difficult to take it. Moreover, if reducing sugars, such as the lactose and powdered sugar in

which protein itself tends to carry out thermal denaturation, and white soft sugar, live together in packing, it is not the method that there is also a defect, such as causing the remarkable appearance change by the Maillard reaction, and it should be satisfied.

[0007]

[Problem(s) to be Solved by the Invention] This invention aims at offering the hard gelatine capsule agent which controls the soluble fall and the insolubilization of a hard gelatine capsule by aging of gelatin, and has the stable drug release nature and by which denaturation was prevented in view of the above—mentioned present condition.

[0008]

[Means for Solving the Problem] Paying attention to a peroxidation reaction being a free radical reaction, wholeheartedly, by carrying out minute amount addition of the compound with high activity which captures a free radical at an encapsulation object, this invention persons find out that a soluble fall and insolubilization of a hard gelatine capsule can be controlled, and came to complete this invention as a result of examination.

[0009] A summary of this invention is in a place which is made to contain a free radical trapping agent 0.01 to 5% of the weight to the packing whole quantity, and constitutes a hard gelatine capsule agent by which denaturation was prevented. In this specification, what has a free radical capture operation (free radical scavenging AKUTI Beatty; henceforth "RSA") as a "free radical trapping agent" is said. Moreover, the number of mols of a free radical which can be captured per one mol of free radical trapping agents is called RSA value. A hard gelatine capsule agent by which the denaturation of this invention was prevented comes to fill up other packing, such as the above—mentioned free radical trapping agent and a drug, and an additive, in a hard gelatine capsule.

[0010] As the above—mentioned free radical trapping agent, especially if it has a free radical capture operation, it will not be limited. A salt which can be permitted especially on an organic compound whose RSA value is 0.01 or more, inorganic compounds, and these medicine manufacture is desirable. For example, a salt which can be permitted on medicine manufacture of a sulfurous acid, a salt which can be permitted on medicine manufacture of a hydrogen sulfite, A cysteine, a glutathione, a tocopherol, an ascorbic acid, a thiamine nitrate, A riboflavin, beta carotene, acetaminophen, chlorpheniramine maleate, Chlorpromazine, pindolol, SESAMI Norian, a gossypol, an soybean saponin, a ROZUMARIN acid, geraniin, quercetine, glycyrrhizic acid, polyphosphoric acid, a pyrophosphoric acid, a metaphosphoric acid, ferric chloride, etc. can be mentioned. A salt which can be permitted among these on a tocopherol, an ascorbic acid, polyphosphoric acid, pyrophosphoric acids, and these medicine manufacture in a salt which can be permitted on medicine manufacture of a sulfurous acid, a salt which can be permitted on medicine manufacture of a hydrogen sulfite, and a list is desirable, and a sodium sulfite, a sodium hydrogensulfite, a tocopherol, a pyrophosphoric acid, a sodium pyrophosphate, a potassium pyrophosphate, etc. are still more desirable.

[0011] A content of the above—mentioned free radical trapping agent is 0.01 — 5 % of the weight to the packing whole quantity which set the above—mentioned free radical trapping agent and other packing. Since insolubilization depressor effect does not become not much large but a configuration of pharmaceutical preparation becomes large too much at reverse even if gelatine capsule insolubilization depressor effect is inadequate in it being less than 0.01 % of the weight and it exceeds 5 % of the weight, it is limited to the above—mentioned range. It is 0.01 — 1 % of the weight preferably.

[0012] Especially if it is except what contains an aldehyde as a component as packing besides the above, it will not be limited, but a drug, an additive, etc. which are generally contained in a capsule may be used suitably. Gestalten of the above—mentioned free radical trapping agent and other packing may be any, such as powder, granulatio, a half—solid, and a solution, and the above—mentioned granulatio may be coated with a basin system or an organic solvent system.

[0013] In this invention, according to combination of a drug used as packing, or an additive, the above—mentioned free radical trapping agent is chosen suitably, and if required, it can be used combining two or more sorts.

[0014] As the above-mentioned hard gelatine capsule, especially if usually used for pharmaceutical preparation, it will not be limited, for example, a No. 3 gelatine capsule etc. is used suitably.

[0015] What is necessary is to be able to perform manufacture of a hard gelatine capsule agent by which the denaturation of this invention was prevented with a conventional method, for example, to carry out simple mixing of the above-mentioned free radical trapping agent, and just to fill up pharmaceutical preparation presentation powder or pharmaceutical preparation presentation granulation with it at this hard gelatine capsule. Depending on the case, the endocyst of this free radical trapping agent may be carried out into the above-mentioned granulation or a coating layer.

[0016] Insolubilization of a gelatine capsule is a phenomenon produced when peroxidation products, such as an aldehyde generated from PEG used in the case of basin system coating, a polyethylene chain in an amphiphilic compound, etc., react with an amino group of gelatin and form a thin film. this invention -- setting -- warming -- a free radical generated by peroxidation of an encapsulation object in the conservation middle class with time is captured by free radical trapping agent, and a peroxidation reaction is controlled. For this reason, even if generation of an aldehyde etc. is controlled and it uses PEG etc. for packing, neither thin film formation of a gelatine capsule nor insolubilization accompanying this is produced.

[0017]

[Example] Although an example is hung up over below and this invention is explained to it in more detail, the range of this invention is not limited by these.

[0018] 2ml of sample solutions which made dissolution or homogeneity distribute a sample to the measurement 0.1M acetic-acid buffer solution (pH5.5) or the methanol of a RSA value, 1ml of 0.6mMDPPH(s) and methanol solutions, a methanol, or 2ml (pH5.5) of 0.1M acetic-acid buffer solutions were put into the stoppered test tube, 530nm absorbance change of the supernatant lightly obtained by carrying out centrifugal separation after a shaking at the room temperature was measured, and the RSA value was calculated.

[0019] The basket which was mixed to example 1 weighing bottle the 5 sections, put into it the free radical trapping agent which shows PEG6000 in the 95 sections and a table 1, and put in the empty No. 3 gelatine capsule on it was placed, and it saved for one week at 60 degrees C in the glass bottle with which they sealed it as a capsule and this mixture maintained the non-contact condition. This capsule was put in into the auxiliary tube for JP12 disintegration tests, and it put into the glassware which filled the 30ml (37 degrees C) of the JP12 2nd \*\*\*\* calmly the whole auxiliary tube, it was left for 5 - 6 minutes, and solubility was observed. The result is shown in a table 1.

[0020]

[A table 1]

フリーラジカル捕獲剤	溶解性
無添加	薄膜形成、不溶化
アスコルビン酸	速やかに溶解
リボフラビン	速やかに溶解
d- $\alpha$ -トコフェロール	速やかに溶解
硝酸チアミン	速やかに溶解
亜硫酸ナトリウム	速やかに溶解

[0021] According to the example 1, the capsule independent [ PEG6000 ] which has not added the free radical trapping agent formed and insolubilized the thin film, but the soluble fall of a capsule was able to be completely inhibited by adding an ascorbic acid, a riboflavin, a tocopherol, a thiamine nitrate, or a sodium sulfite, respectively.

[0022] The constituent which added the various compounds shown in a table 2 into the KOTIDDO granulation (henceforth "Mixture A") which mixed 30.0mg [ of example 2 crystalline

cellulose ], 10.0mg [ of pyridoxine hydrochlorides ], 54.0mg [ of lactoses ], and corn-starch 5.0mg, talc 31.5mg, Aerosil 0.3mg, 1.2mg [ of magnesium stearates ], and citric-acid triethyl 7.7mg, HPC-L0.5mg, and HPMC-AS38.3mg was prepared. The No. 3 gelatine capsule was filled up with this, and the elution test after conservation was performed for five days at 60 degrees C into the sealed glass bottle. It carried out with the method paddle method of a station (paddle rotational frequency 100 rotation), using the 900ml of the JP12 2nd liquid as an eluate. The result is shown in drawing 1 and drawing 2.

[0023]

[A table 2]

化 合 物	配 合 ( m g )								
	製 剤 A	製 剤 B	製 剤 C	製 剤 D	製 剤 E	製 剤 F	製 剤 G	製 剤 H	製 剤 I
混 合 物 A	178.5	178.5	178.5	178.5	178.5	178.5	178.5	178.5	178.5
リン酸二水素ナトリウム	—	0.7	—	—	—	—	—	—	—
エテンザミド	—	—	0.7	—	—	—	—	—	—
アスピリン	—	—	—	0.7	—	—	—	—	—
アセトアミノフェン	—	—	—	—	0.7	—	—	—	—
システイン	—	—	—	—	—	0.7	—	—	—
ピロリン酸ナトリウム	—	—	—	—	—	—	0.7	—	—
亜硫酸ナトリウム	—	—	—	—	—	—	—	0.5	—
亜硫酸水素ナトリウム	—	—	—	—	—	—	—	—	0.5
合 計	178.5	179.2	179.2	179.2	179.2	179.2	179.2	179.0	179.0

[0024] the pharmaceutical preparation B, C, and D which added the sodium dihydrogenphosphate, ethenzamide, or aspirin which does not have the free radical capture operation in the pharmaceutical preparation A list of Mixture A, respectively according to the example 2 — warming — insolubilization of a capsule was produced after conservation and drug release nature fell remarkably. the pharmaceutical preparation E, F, G, H, and I which, on the other hand, added the big acetaminophen, the cysteine, the sodium pyrophosphate, sodium sulfite, or sodium hydrogensulfite of a RSA value, respectively — warming — insolubilization of a capsule was not produced after conservation and the fall of drug release nature was not accepted.

[0025] The free radical trapping agent shown in example 3 table 3 was mixed in the five sections, PEG4000 was mixed with 95 section mortar, and the gelatin No. 3 capsule was filled up. Packing was removed after one-week conservation at 60 degrees C in the sealed glass bottle, and the solubility of a capsule was investigated like the example 1. The result is shown in a table 3.

[0026]

[A table 3]

フリーラジカル捕獲剤	溶解性
無添加	薄膜形成、不溶化
d- $\alpha$ -トコフェロール	速やかに溶解
ポリリン酸	速やかに溶解
メタリン酸	速やかに溶解
グルタチオン	速やかに溶解

[0027] the case where according to the example 3 the capsule formed and insolubilized the thin film when a free radical trapping agent was not added, but it adds — warming — the

soluble fall of a capsule was not accepted after conservation.

[0028] The example 4 ethenzamide 10 section and tocopherol, cysteine, or sodium-sulfite 5 section was dissolved in the Tween80 (trade name) 50 section and the Span20 (trade name) 35 section. The gelatine capsule was filled up with it and the elution test was performed like the example 2 after one-week conservation at 60 degrees C into the sealed glass bottle. The result is shown in drawing 3.

[0029] According to the example 4, when free radical trapping agents, such as a tocopherol, were not added, the capsule was insolubilized, the remarkable fall of drug release nature was accepted, but when it added, insolubilization of a capsule was not produced and the fall of drug release nature was not accepted, either.

[0030]

[Effect of the Invention] By this invention, a soluble fall with time and insolubilization are prevented, and the hard gelatine capsule agent which has the stable drug release nature and by which denaturation was prevented can be offered.

---

[Translation done.]

**\* NOTICES \***

**Japan Patent Office is not responsible for any damages caused by the use of this translation.**

- 1.This document has been translated by computer. So the translation may not reflect the original precisely.
- 2.\*\*\*\* shows the word which can not be translated.
- 3.In the drawings, any words are not translated.

---

**TECHNICAL FIELD**

---

[A technical field to which invention belongs] A soluble fall with time and insolubilization are prevented and this invention relates to a hard gelatine capsule agent which has stable drug release nature and by which denaturation was prevented, and its manufacture method.

---

[Translation done.]

---



## \* NOTICES \*

**Japan Patent Office is not responsible for any damages caused by the use of this translation.**

- 1.This document has been translated by computer. So the translation may not reflect the original precisely.
- 2.\*\*\*\* shows the word which can not be translated.
- 3.In the drawings, any words are not translated.

---



---

PRIOR ART

---



---

[Description of the Prior Art] Into the hard gelatine capsule, a hard gelatine capsule agent is what was filled up with packing, such as a drug, and is used for various kinds of purpose, such as improvement in the handling nature of a drug. In layout of the pharmaceutical preparation which contains an unstable drug in an acid, a sustained release drug, etc., since a difference is produced in a bioavailability among the persons prescribed a medicine for the patient when it considers as a tablet, generally considering as a hard gelatine capsule agent for the purpose of the evasion is performed.

[0003] For example, in order to make small the difference of the absorption coefficient in intestines by difference of the alimentary canal internal transmigration speed of a drug, basin system coating of the granulatio of a drug is carried out with an enteric macromolecule or a water-insoluble nature macromolecule, and the method of filling up a hard gelatine capsule is often used. Moreover, in order to improve the wettability over the water of a poorly soluble drug, also when adding amphiphilic compounds, such as Tween (trade name), Span (trade name), and a polyethylene glycol (PEG), the method of making it into a hard gelatine capsule agent for evasion, such as deterioration of appearance, is used.

[0004] however, the case where a hard gelatine capsule is filled up with the amphiphilic compound which has granulatio and the polyoxyethylene chain of the drug which carried out basin system coating in the above-mentioned method — warming — a hard gelatine capsule may deteriorate at the time of conservation, and drug release nature may fall remarkably As this cause, the polyoxyethylene chain in compounds and amphiphilic compounds, such as PEG used as a plasticizer in the case of basin system coating and citric-acid triethyl, etc. pyrolyzes, and gelatin can consider bridge formation and carrying out a polymerization between intramolecular or a molecule by peroxidation products, such as an aldehyde which this generates.

[0005] Using the organic solvent which does not use a plasticizer in the case of coating as the above-mentioned cure is mentioned. However, this method is not desirable from being in the orientation for there to be a problem of a residual solvent and for use of an organic solvent to be regulated from viewpoints, such as environmental pollution, in recent years. Although using plasticizers which do not generate a peroxide, such as a triacetin and glycerol monostearate, is also considered, there is a defect of dispersing odors, such as an acetic-acid smell to which the bad plasticizer itself carries out acidolysis, and acid resistance and drug release nature deteriorate with time, and the plasticity of a film is not desirable too.

[0006] Moreover, the method of adding protein, such as casein, soybean protein, skim milk, and a collagen, in an encapsulation object is learned as other methods (JP,51-15094,A). However, this method does not control generation of a peroxide, since it needs to make [ many ] an addition for acquiring a desired effect, a capsule enlarges it and it becomes difficult to take it. Moreover, if reducing sugars, such as the lactose and powdered sugar in which protein itself tends to carry out thermal denaturation, and white soft sugar, live together in packing, it is not the method that there is also a defect, such as causing the remarkable appearance change by the Maillard reaction, and it should be satisfied.

---



---

[Translation done.]

**\* NOTICES \***

**Japan Patent Office is not responsible for any damages caused by the use of this translation.**

- 1.This document has been translated by computer. So the translation may not reflect the original precisely.
- 2.\*\*\* shows the word which can not be translated.
- 3.In the drawings, any words are not translated.

---

**EFFECT OF THE INVENTION**

---

[Effect of the Invention] By this invention, a soluble fall with time and insolubilization are prevented, and the hard gelatine capsule agent which has the stable drug release nature and by which denaturation was prevented can be offered.

---

[Translation done.]

---

**\* NOTICES \***

**Japan Patent Office is not responsible for any damages caused by the use of this translation.**

- 1.This document has been translated by computer. So the translation may not reflect the original precisely.
- 2.\*\*\* shows the word which can not be translated.
- 3.In the drawings, any words are not translated.

---

**TECHNICAL PROBLEM**

---

[Problem(s) to be Solved by the Invention] This invention aims at offering the hard gelatine capsule agent which controls the soluble fall and the insolubilization of a hard gelatine capsule by aging of gelatin, and has the stable drug release nature and by which denaturation was prevented in view of the above-mentioned present condition.

---

[Translation done.]

---

## \* NOTICES \*

Japan Patent Office is not responsible for any damages caused by the use of this translation.

- 1.This document has been translated by computer. So the translation may not reflect the original precisely.
- 2.\*\*\* shows the word which can not be translated.
- 3.In the drawings, any words are not translated.

---

MEANS

---

[Means for Solving the Problem] Paying attention to a peroxidation reaction being a free radical reaction, wholeheartedly, by carrying out minute amount addition of the compound with high activity which captures a free radical at an encapsulation object, this invention persons find out that a soluble fall and insolubilization of a hard gelatine capsule can be controlled, and came to complete this invention as a result of examination.

[0009] A summary of this invention is in a place which is made to contain a free radical trapping agent 0.01 to 5% of the weight to the packing whole quantity, and constitutes a hard gelatine capsule agent by which denaturation was prevented. In this specification, what has a free radical capture operation (free radical scavenging AKUTI Beatty; henceforth "RSA") as a "free radical trapping agent" is said. Moreover, the number of mols of a free radical which can be captured per one mol of free radical trapping agents is called RSA value. A hard gelatine capsule agent by which the denaturation of this invention was prevented comes to fill up other packing, such as the above-mentioned free radical trapping agent and a drug, and an additive, in a hard gelatine capsule.

[0010] As the above-mentioned free radical trapping agent, especially if it has a free radical capture operation, it will not be limited. A salt which can be permitted especially on an organic compound whose RSA value is 0.01 or more, inorganic compounds, and these medicine manufacture is desirable. For example, a salt which can be permitted on medicine manufacture of a sulfurous acid, a salt which can be permitted on medicine manufacture of a hydrogen sulfite, A cysteine, a glutathione, a tocopherol, an ascorbic acid, a thiamine nitrate, A riboflavin, beta carotene, acetaminophen, chlorpheniramine maleate, Chlorpromazine, pindolol, SESAMI Norian, a gossypol, an soybean saponin, a ROZUMARIN acid, geraniin, quercetine, glycyrrhizic acid, polyphosphoric acid, a pyrophosphoric acid, a metaphosphoric acid, ferric chloride, etc. can be mentioned. A salt which can be permitted among these on a tocopherol, an ascorbic acid, polyphosphoric acid, pyrophosphoric acids, and these medicine manufacture in a salt which can be permitted on medicine manufacture of a sulfurous acid, a salt which can be permitted on medicine manufacture of a hydrogen sulfite, and a list is desirable, and a sodium sulfite, a sodium hydrogensulfite, a tocopherol, a pyrophosphoric acid, a sodium pyrophosphate, a potassium pyrophosphate, etc. are still more desirable.

[0011] A content of the above-mentioned free radical trapping agent is 0.01 - 5 % of the weight to the packing whole quantity which set the above-mentioned free radical trapping agent and other packing. Since insolubilization depressor effect does not become not much large but a configuration of pharmaceutical preparation becomes large too much at reverse even if gelatine capsule insolubilization depressor effect is inadequate in it being less than 0.01 % of the weight and it exceeds 5 % of the weight, it is limited to the above-mentioned range. It is 0.01 - 1 % of the weight preferably.

[0012] Especially if it is except what contains an aldehyde as a component as packing besides the above, it will not be limited, but a drug, an additive, etc. which are generally contained in a capsule may be used suitably. Gestalten of the above-mentioned free radical trapping agent and other packing may be any, such as powder, granulation, a half-solid, and a solution, and the above-mentioned granulation may be coated with a basin system or an organic solvent system.

[0013] In this invention, according to combination of a drug                      used as packing, or an additive,

the above-mentioned free radical trapping agent is chosen suitably, and if required, it can be used combining two or more sorts.

[0014] As the above-mentioned hard gelatine capsule, especially if usually used for pharmaceutical preparation, it will not be limited, for example, a No. 3 gelatine capsule etc. is used suitably.

[0015] What is necessary is to be able to perform manufacture of a hard gelatine capsule agent by which the denaturation of this invention was prevented with a conventional method, for example, to carry out simple mixing of the above-mentioned free radical trapping agent, and just to fill up pharmaceutical preparation presentation powder or pharmaceutical preparation presentation granulation with it at this hard gelatine capsule. Depending on the case, the endocyst of this free radical trapping agent may be carried out into the above-mentioned granulation or a coating layer.

[0016] Insolubilization of a gelatine capsule is a phenomenon produced when peroxidation products, such as an aldehyde generated from PEG used in the case of basin system coating, a polyethylene chain in an amphiphilic compound, etc., react with an amino group of gelatin and form a thin film. this invention -- setting -- warming -- a free radical generated by peroxidation of an encapsulation object in the conservation middle class with time is captured by free radical trapping agent, and a peroxidation reaction is controlled. For this reason, even if generation of an aldehyde etc. is controlled and it uses PEG etc. for packing, neither thin film formation of a gelatine capsule nor insolubilization accompanying this is produced.

---

[Translation done.]

## \* NOTICES \*

Japan Patent Office is not responsible for any damages caused by the use of this translation.

- 1.This document has been translated by computer. So the translation may not reflect the original precisely.
- 2.\*\*\* shows the word which can not be translated.
- 3.In the drawings, any words are not translated.

## EXAMPLE

[Example] Although an example is hung up over below and this invention is explained to it in more detail, the range of this invention is not limited by these.

[0018] 2ml of sample solutions which made dissolution or homogeneity distribute a sample to the measurement 0.1M acetic-acid buffer solution (pH5.5) or the methanol of a RSA value, 1ml of 0.6mMDPPH(s) and methanol solutions, a methanol, or 2ml (pH5.5) of 0.1M acetic-acid buffer solutions were put into the stoppered test tube, 530nm absorbance change of the supernatant lightly obtained by carrying out centrifugal separation after a shaking at the room temperature was measured, and the RSA value was calculated.

[0019] The basket which was mixed to example 1 weighing bottle the 5 sections, put into it the free radical trapping agent which shows PEG6000 in the 95 sections and a table 1, and put in the empty No. 3 gelatine capsule on it was placed, and it saved for one week at 60 degrees C in the glass bottle with which they sealed it as a capsule and this mixture maintained the non-contact condition. This capsule was put in into the auxiliary tube for JP12 disintegration tests, and it put into the glassware which filled the 30ml (37 degrees C) of the JP12 2nd \*\*\* calmly the whole auxiliary tube, it was left for 5 - 6 minutes, and solubility was observed. The result is shown in a table 1.

[0020]

[A table 1]

フリーラジカル捕獲剤	溶解性
無添加	薄膜形成、不溶化
アスコルビン酸	速やかに溶解
リボフラビン	速やかに溶解
d- $\alpha$ -トコフェロール	速やかに溶解
硝酸チアミン	速やかに溶解
亜硫酸ナトリウム	速やかに溶解

[0021] According to the example 1, the capsule independent [ PEG6000 ] which has not added the free radical trapping agent formed and insolubilized the thin film, but the soluble fall of a capsule was able to be completely inhibited by adding an ascorbic acid, a riboflavin, a tocopherol, a thiamine nitrate, or a sodium sulfite, respectively.

[0022] The constituent which added the various compounds shown in a table 2 into the KOTIDDO granulation (henceforth "Mixture A") which mixed 30.0mg [ of example 2 crystalline cellulose ], 10.0mg [ of pyridoxine hydrochlorides ], 54.0mg [ of lactoses ], and corn-starch 5.0mg, talc 31.5mg, Aerosil 0.3mg, 1.2mg [ of magnesium stearates ], and citric-acid triethyl 7.7mg, HPC-L0.5mg, and HPMC-AS38.3mg was prepared. The No. 3 gelatine capsule was filled up with this, and the elution test after conservation was performed for five days at 60 degrees C into the sealed glass bottle. It carried out with the method paddle method of a station (paddle rotational frequency 100 rotation), using the 900ml of the JP12 2nd liquid as an eluate. The result is shown in drawing 1 and drawing 2.

[0023]

[A table 2]

化 合 物	配 合 ( m g )									
	製 剤 A	製 剤 B	製 剤 C	製 剤 D	製 剤 E	製 剤 F	製 剤 G	製 剤 H	製 剤 I	
混 合 物 A	178. 5	178. 5	178. 5	178. 5	178. 5	178. 5	178. 5	178. 5	178. 5	
リン酸二水素ナトリウム	—	0. 7	—	—	—	—	—	—	—	
エテンザミド	—	—	0. 7	—	—	—	—	—	—	
アスピリン	—	—	—	0. 7	—	—	—	—	—	
アセトアミノフェン	—	—	—	—	0. 7	—	—	—	—	
システイン	—	—	—	—	—	0. 7	—	—	—	
ピロリン酸ナトリウム	—	—	—	—	—	—	0. 7	—	—	
亜硫酸ナトリウム	—	—	—	—	—	—	—	0. 5	—	
亜硫酸水素ナトリウム	—	—	—	—	—	—	—	—	0. 5	
合 計	178. 5	179. 2	179. 2	179. 2	179. 2	179. 2	179. 2	179. 0	179. 0	

[0024] the pharmaceutical preparation B, C, and D which added the sodium dihydrogenphosphate, ethenzamide, or aspirin which does not have the free radical capture operation in the pharmaceutical preparation A list of Mixture A, respectively according to the example 2 — warming — insolubilization of a capsule was produced after conservation and drug release nature fell remarkably. the pharmaceutical preparation E, F, G, H, and I which, on the other hand, added the big acetaminophen, the cysteine, the sodium pyrophosphate, sodium sulfite, or sodium hydrogensulfite of a RSA value, respectively — warming — insolubilization of a capsule was not produced after conservation and the fall of drug release nature was not accepted.

[0025] The free radical trapping agent shown in example 3 table 3 was mixed in the five sections, PEG4000 was mixed with 95 section mortar, and the gelatin No. 3 capsule was filled up. Packing was removed after one-week conservation at 60 degrees C in the sealed glass bottle, and the solubility of a capsule was investigated like the example 1. The result is shown in a table 3.

[0026]

[A table 3]

フリーラジカル捕獲剤	溶解性
無添加	薄膜形成、不溶化
d- $\alpha$ -トコフェロール	速やかに溶解
ポリリン酸	速やかに溶解
メタリン酸	速やかに溶解
グルタチオン	速やかに溶解

[0027] the case where according to the example 3 the capsule formed and insolubilized the thin film when a free radical trapping agent was not added, but it adds — warming — the soluble fall of a capsule was not accepted after conservation.

[0028] The example 4 ethenzamide 10 section and tocopherol, cysteine, or sodium-sulfite 5 section was dissolved in the Tween80 (trade name) 50 section and the Span20 (trade name) 35 section. The gelatine capsule was filled up with it and the elution test was performed like the example 2 after one-week conservation at 60 degrees C into the sealed glass bottle. The result is shown in drawing 3.

[0029] According to the example 4, when free radical trapping agents, such as a tocopherol,

were not added, the capsule was insolubilized, the remarkable fall of drug release nature was accepted, but when it added, insolubilization of a capsule was not produced and the fall of drug release nature was not accepted, either.

---

[Translation done.]



**\* NOTICES \***

**Japan Patent Office is not responsible for any damages caused by the use of this translation.**

- 1.This document has been translated by computer. So the translation may not reflect the original precisely.
- 2.\*\*\* shows the word which can not be translated.
- 3.In the drawings, any words are not translated.

---

**DESCRIPTION OF DRAWINGS**

---

[Brief Description of the Drawings]

[Drawing 1] The drug release curve of the hard gelatine capsule agent in an example 2.

[Drawing 2] The drug release curve of the hard gelatine capsule agent in an example 2.

[Drawing 3] The drug release curve of the hard gelatine capsule agent in an example 4.

---

[Translation done.]

## \* NOTICES \*

Japan Patent Office is not responsible for any damages caused by the use of this translation.


1. This document has been translated by computer. So the translation may not reflect the original precisely.

2.\*\*\* shows the word which can not be translated.


3. In the drawings, any words are not translated.

## DRAWINGS


[Drawing 1]



[Drawing 2]



[Drawing 3]



[Translation done.]

(19) 日本国特許庁 (J P)

(12) 公 開 特 許 公 報 (A)

(11) 特許出願公開番号

特開平8-99869

(43) 公開日 平成8年(1996)4月16日

(51) Int.Cl. <sup>8</sup>	識別記号	庁内整理番号	F I	技術表示箇所
A 6 1 K 9/48	B			
47/04	J			
47/22	J			

審査請求 未請求 請求項の数 8 F D (全 6 頁)

(21) 出願番号	特願平7-219756	(71) 出願人	000001926 塩野義製薬株式会社 大阪府大阪市中央区道修町3丁目1番8号
(22) 出願日	平成7年(1995)8月4日	(72) 発明者	佐久間 聡 大津市におの浜二丁目二番1-106
(31) 優先権主張番号	特願平6-204322	(72) 発明者	鈴木 裕介 大阪府和泉市府中町5丁目15-15
(32) 優先日	平6(1994)8月5日	(72) 発明者	藤井 歳郎 兵庫県宝塚市武庫山1丁目1-1
(33) 優先権主張国	日本 (J P)	(72) 発明者	小倉 敏弘 大阪府吹田市青山台2丁目7番 A 4-107
		(74) 代理人	弁理士 安富 康男 (外1名) 最終頁に続く

(54) 【発明の名称】 変性の防止された硬質ゼラチンカプセル剤及びその製造方法

(57) 【要約】

【課題】 ゼラチンの経時変化による硬質ゼラチンカプセルの溶解性の低下及び不溶化を防止し、安定した薬物放出性を有する変性の防止された硬質ゼラチンカプセル剤を提供する。

【解決手段】 フリーラジカル捕獲剤を充填物全量に対して0.01~5重量%含有する変性の防止された硬質ゼラチンカプセル剤。

## 【特許請求の範囲】

【請求項 1】 フリーラジカル捕獲剤を充填物全量に対して 0.01～5 重量%含有することを特徴とする変性の防止された硬質ゼラチンカプセル剤。

【請求項 2】 フリーラジカル捕獲剤の含有量が、充填物全量に対して 0.01～1 重量%である請求項 1 記載の変性の防止された硬質ゼラチンカプセル剤。

【請求項 3】 フリーラジカル捕獲剤が、亜硫酸の製薬上許容しうる塩、亜硫酸水素の製薬上許容しうる塩、並びに、トコフェロール、アスコルビン酸、ピロリン酸、ピロリン酸及びこれらの製薬上許容しうる塩からなる群より選択された少なくとも 1 種である請求項 1 又は 2 記載の変性の防止された硬質ゼラチンカプセル剤。

【請求項 4】 フリーラジカル捕獲剤が、亜硫酸ナトリウムである請求項 3 記載の変性の防止された硬質ゼラチンカプセル剤。

【請求項 5】 フリーラジカル捕獲剤が、亜硫酸水素ナトリウムである請求項 3 記載の変性の防止された硬質ゼラチンカプセル剤。

【請求項 6】 フリーラジカル捕獲剤が、ピロリン酸ナトリウム又はピロリン酸カリウムである請求項 3 記載の変性の防止された硬質ゼラチンカプセル剤。

【請求項 7】 硬質ゼラチンカプセル剤の製造方法において、フリーラジカル捕獲剤を充填物全量に対して 0.01～5 重量%含有させることを特徴とする変性の防止された硬質ゼラチンカプセル剤の製造方法。

【請求項 8】 フリーラジカル捕獲剤の含有量が、充填物全量に対して 0.01～1 重量%である請求項 7 記載の変性の防止された硬質ゼラチンカプセル剤の製造方法。

## 【発明の詳細な説明】

## 【0001】

【発明の属する技術分野】 本発明は、経時的な溶解性の低下、不溶化が防止され、安定した薬物放出性を有する変性の防止された硬質ゼラチンカプセル剤及びその製造方法に関する。

## 【0002】

【従来の技術】 硬質ゼラチンカプセル剤は、硬質ゼラチンカプセル中に薬物等の充填物を充填したもので、薬物の取扱い性の向上等各種の目的で使用されている。酸に不安定な薬物を含有する製剤や徐放性製剤等の設計において、錠剤とした場合には、被投与者間でバイオアベイラビリティに差を生じるため、その回避を目的として硬質ゼラチンカプセル剤とすることが一般的に行われている。

【0003】 例えば、薬物の消化管内移動速度の相違による腸内吸収率の差を小さくするため、腸溶性高分子や水不溶性高分子で薬物の顆粒を水系コーティングし、硬質ゼラチンカプセルに充填する方法がしばしば用いられる。また、難溶性薬物の水に対するぬれ性を改善するた

めに、Tween（商品名）、Span（商品名）、ポリエチレングリコール（PEG）等の両親媒性化合物を添加する場合にも、外観の劣化等の回避のために硬質ゼラチンカプセル剤とする方法が用いられる。

【0004】 しかし、上記方法において、水系コーティングした薬物の顆粒やポリオキシエチレン鎖を有する両親媒性化合物を硬質ゼラチンカプセルに充填した場合、加温保存時に硬質ゼラチンカプセルが変質し、薬物放出性が著しく低下することがある。この原因としては、水系コーティングの際に可塑剤として使用される PEG、クエン酸トリエチル等の化合物や両親媒性化合物中のポリオキシエチレン鎖等が熱分解し、これにより生成するアルデヒド等の過酸化生成物により、ゼラチンが分子内又は分子間で架橋、重合することが考えられる。

【0005】 上記の対策として、例えば、コーティングの際に、可塑剤を使用しない有機溶媒を用いることが挙げられる。しかし、この方法は、残留溶媒の問題があり、また、環境汚染等の観点から有機溶媒の使用が近年規制される傾向にあることから、望ましいものではない。過酸化物を生成しないトリアセチン、グリセリンモノステアレート等の可塑剤を用いることも考えられるが、フィルムの形成性が悪い、可塑剤自体が酸分解し経時的に耐酸性や薬物放出性が劣化する、酢酸臭等の臭気を飛散する等の欠点があり、やはり好ましいものではない。

【0006】 また、他の方法として、カプセル充填物にカゼイン、大豆タンパク質、スキムミルク、コラーゲン等のタンパク質を添加する方法が知られている（特開昭 51-15094 号公報）。しかし、この方法は、過酸化物の生成を抑制するものではなく、所望の効果をj得るには添加量を多くする必要があるため、カプセル剤が大型化して服用が困難となる。また、タンパク質自体が熱変性しやすい、乳糖、粉糖、白糖等の還元糖が充填物中に共存していると、メイラード反応による著しい外観変化をきたす、等の欠点もあり、満足すべき方法ではない。

## 【0007】

【発明が解決しようとする課題】 本発明は、上記現状に鑑み、ゼラチンの経時変化による硬質ゼラチンカプセルの溶解性の低下及び不溶化を抑制し、安定した薬物放出性を有する変性の防止された硬質ゼラチンカプセル剤を提供することを目的とするものである。

## 【0008】

【課題を解決するための手段】 本発明者らは、過酸化反応がフリーラジカル反応であることに着目し、鋭意検討の結果、フリーラジカルを捕獲する活性の高い化合物をカプセル充填物に微量添加することにより、硬質ゼラチンカプセルの溶解性の低下や不溶化を抑制することができるを見だし、本発明を完成するに至った。

【0009】 本発明の要旨は、変性の防止された硬質ゼ

ラチンカプセル剤を、フリーラジカル捕獲剤を充填物全量に対して 0.01~5 重量% 含有させて構成するところにある。本明細書において、「フリーラジカル捕獲剤」とは、フリーラジカル捕獲作用（フリーラジカル・スカベンジング・アクティビティ；以下「RSA」ともいう）を有するものをいう。また、フリーラジカル捕獲剤 1 モルあたり捕獲することができるフリーラジカルのモル数を、RSA 値という。本発明の変性の防止された硬質ゼラチンカプセル剤は、硬質ゼラチンカプセル内に上記フリーラジカル捕獲剤及び薬物、添加剤等の他の充填物を充填してなる。

【0010】上記フリーラジカル捕獲剤としては、フリーラジカル捕獲作用を有しているものであれば特に限定されず、なかでも RSA 値が 0.01 以上である有機化合物、無機化合物及びこれらの製薬上許容しうる塩が好ましく、例えば、亜硫酸の製薬上許容しうる塩、亜硫酸水素の製薬上許容しうる塩、システイン、グルタチオン、トコフェロール、アスコルビン酸、硝酸チアミン、リボフラビン、β-カロチン、アセトアミノフェン、マレイン酸クロルフェニラミン、クロルプロマジン、ピンドロール、セサミノール、ゴシポール、大豆サポニン、ロズマリン酸、ゲラニイン、ケルセチン、グリチルリチン酸、ポリリン酸、ピロリン酸、メタリン酸、塩化第 2 鉄等を挙げることができる。これらのうち、亜硫酸の製薬上許容しうる塩、亜硫酸水素の製薬上許容しうる塩、並びに、トコフェロール、アスコルビン酸、ポリリン酸、ピロリン酸及びこれらの製薬上許容しうる塩等が好ましく、亜硫酸ナトリウム、亜硫酸水素ナトリウム、トコフェロール、ピロリン酸、ピロリン酸ナトリウム、ピロリン酸カリウム等がさらに好ましい。

【0011】上記フリーラジカル捕獲剤の含有量は、上記フリーラジカル捕獲剤及び他の充填物を合わせた充填物全量に対して 0.01~5 重量% である。0.01 重量% 未満であるとゼラチンカプセル不溶化抑制効果が不充分であり、5 重量% を超えても不溶化抑制効果はあまり大きくならず、逆に製剤の形状が大きくなりすぎるため、上記範囲に限定される。好ましくは 0.01~1 重量% である。

【0012】上記他の充填物としては、成分としてアルデヒドを含有するもの以外であれば特に限定されず、カプセル剤中に一般に含有される薬物及び添加剤等が好適に用いられ得る。上記フリーラジカル捕獲剤及び他の充填物の形態は、粉末、顆粒、半固形、溶液等のいずれであってもよく、また、上記顆粒は水系あるいは有機溶媒系でコーティングしたものであってもよい。

【0013】本発明においては、充填物として使用される薬物や添加剤の組み合わせに応じて、上記フリーラジカル捕獲剤を適宜選択し必要であれば 2 種以上を組み合わせ使用することができる。

【0014】上記硬質ゼラチンカプセルとしては、通常

製剤に用いられるものであれば特に限定されず、例えば、3 号ゼラチンカプセル等が好適に用いられる。

【0015】本発明の変性の防止された硬質ゼラチンカプセル剤の製造は、常法により行うことができ、例えば、上記フリーラジカル捕獲剤は、製剤組成粉末又は製剤組成顆粒に単純混合して該硬質ゼラチンカプセルに充填すればよい。場合によっては、上記顆粒内又はコーティング層内に該フリーラジカル捕獲剤を内包させてもよい。

【0016】ゼラチンカプセルの不溶化は、水系コーティングの際に使用される PEG や両親媒性化合物中のポリエチレン鎖等から発生するアルデヒド等の過酸化生成物がゼラチンのアミノ基と反応し、薄膜を形成することにより生じる現象である。本発明においては、加温保存中等におけるカプセル充填物の経時的過酸化によって発生するフリーラジカルは、フリーラジカル捕獲剤によって捕獲され、過酸化反応が抑制される。このため、アルデヒド等の生成が抑制され、充填物に PEG 等を使用しても、ゼラチンカプセルの薄膜形成や、これに伴う不溶化を生じない。

【0017】

【実施例】以下に実施例を掲げて本発明をさらに詳しく説明するが、本発明の範囲がこれらにより限定されるものではない。

【0018】RSA 値の測定

0.1 M 酢酸緩衝液 (pH 5.5) 又はメタノールに試料を溶解又は均一に分散させた試料液 2 ml、0.6 mMDPPH・メタノール溶液 1 ml、及び、メタノール又は 0.1 M 酢酸緩衝液 (pH 5.5) 2 ml を共栓付き試験管に入れ、室温で軽く振とう後、遠心分離し、得られた上澄み液の 530 nm の吸光度変化を測定して RSA 値を求めた。

【0019】実施例 1

秤量瓶に PEG 6000 を 95 部、表 1 に示すフリーラジカル捕獲剤を 5 部混合して入れ、その上に空の 3 号ゼラチンカプセルを入れたバスケットを置き、カプセルとこの混合物が非接触の状態を保つようにして密栓したガラス瓶中に 60℃ で 1 週間保存した。このカプセルを J P 12 崩壊試験用の補助筒の中に入れ、J P 12 第 2 液約 30 ml (37℃) を満たしたガラス容器に補助筒ごと静かに入れ、5~6 分間放置して溶解性を観察した。その結果を表 1 に示す。

【0020】

【表 1】

フリーラジカル捕獲剤	溶解性
無添加	薄膜形成、不溶化
アスコルビン酸	速やかに溶解
リボフラビン	速やかに溶解
d- $\alpha$ -トコフェロール	速やかに溶解
硝酸チアミン	速やかに溶解
亜硫酸ナトリウム	速やかに溶解

【0021】実施例1によれば、フリーラジカル捕獲剤を添加していないPEG6000単独のカプセルは薄膜を形成し、不溶化したが、アスコルビン酸、リボフラビン、トコフェロール、硝酸チアミン又は亜硫酸ナトリウムをそれぞれ添加することによりカプセルの溶解性の低

化 合 物	配合 (mg)									
	製 剤 A	製 剤 B	製 剤 C	製 剤 D	製 剤 E	製 剤 F	製 剤 G	製 剤 H	製 剤 I	
混 合 物 A	178.5	178.5	178.5	178.5	178.5	178.5	178.5	178.5	178.5	
リン酸二水素ナトリウム	—	0.7	—	—	—	—	—	—	—	
エテンザミド	—	—	0.7	—	—	—	—	—	—	
アスピリン	—	—	—	0.7	—	—	—	—	—	
アセトアミノフェン	—	—	—	—	0.7	—	—	—	—	
システイン	—	—	—	—	—	0.7	—	—	—	
ピロリン酸ナトリウム	—	—	—	—	—	—	0.7	—	—	
亜硫酸ナトリウム	—	—	—	—	—	—	—	0.5	—	
亜硫酸水素ナトリウム	—	—	—	—	—	—	—	—	0.5	
合 計	178.5	179.2	179.2	179.2	179.2	179.2	179.2	179.0	179.0	

【0024】実施例2によれば、混合物Aのみの製剤A並びにフリーラジカル捕獲作用を有していないリン酸二水素ナトリウム、エテンザミド又はアスピリンをそれぞれ添加した製剤B、C及びDは加温保存後にはカプセルの不溶化を生じ、薬物放出性が著しく低下した。一方、RSA値の大きなアセトアミノフェン、システイン、ピロリン酸ナトリウム、亜硫酸ナトリウム又は亜硫酸水素ナトリウムをそれぞれ添加した製剤E、F、G、H及びIは加温保存後でもカプセルの不溶化を生じず、薬物放

【0025】実施例3

表3に示すフリーラジカル捕獲剤を5部、PEG4000を95部乳鉢で混合し、ゼラチン3号カプセルに充填した。密栓したガラス瓶中に60℃で1週間保存後、充填物を除去し、実施例1と同様にしてカプセルの溶解性を調べた。その結果を表3に示す。

【0026】

【表3】

下を完全に抑止することができた。

【0022】実施例2

結晶セルロース30.0mg、塩酸ピリドキシン10.0mg、乳糖54.0mg、コーンスターチ5.0mg、タルク31.5mg、アエロジル0.3mg、ステアリン酸マグネシウム1.2mg、クエン酸トリエチル7.7mg、HPC-L0.5mg、HPMC-AS38.3mgを混合したコーティッド顆粒（以下「混合物A」という）に表2に示す種々の化合物を添加した組成物を調製した。これを3号ゼラチンカプセルに充填し、密栓したガラス瓶中に60℃で5日間保存後溶出試験を行った。溶出液としてJP12第2液900mlを用い、局方パドル法（パドル回転数100回転）で行った。その結果を図1及び図2に示す。

【0023】

【表2】

フリーラジカル捕獲剤	溶解性
無添加	薄膜形成、不溶化
d- $\alpha$ -トコフェロール	速やかに溶解
ポリリン酸	速やかに溶解
メタリン酸	速やかに溶解
グルタチオン	速やかに溶解

【0027】実施例3によれば、フリーラジカル捕獲剤を添加しない場合はカプセルが薄膜を形成し不溶化したが、添加した場合は、加温保存後でもカプセルの溶解性の低下は認められなかった。

【0028】実施例4

エテンザミド10部及びトコフェロール、システイン又は亜硫酸ナトリウム5部を、Tween80（商品名）50部及びSpan20（商品名）35部に溶解した。それをゼラチンカプセルに充填し、密栓したガラス瓶中に60℃で1週間保存後、実施例2と同様にして溶出試


験を行った。その結果を図3に示す。

【0029】実施例4によれば、トコフェロール等のフリーラジカル捕獲剤を添加しない場合は、カプセルは不溶化し、著しい薬物放出性の低下が認められたが、添加した場合はカプセルの不溶化は生じず、薬物放出性の低下も認められなかった。


【0030】

【発明の効果】本発明により、経時的な溶解性の低下及び不溶化が防止され、安定した薬物放出性を有する変性

【図1】



【図3】



の防止された硬質ゼラチンカプセル剤を提供することができる。


【図面の簡単な説明】

【図1】実施例2における硬質ゼラチンカプセル剤の薬物放出曲線。

【図2】実施例2における硬質ゼラチンカプセル剤の薬物放出曲線。

【図3】実施例4における硬質ゼラチンカプセル剤の薬物放出曲線。

【図2】





フロントページの続き

(72)発明者 高岸 靖  
兵庫県芦屋市潮見町27-1